Skip to content
Caprelsa(vandetanib)
Caprelsa (vandetanib) is a small molecule pharmaceutical. Vandetanib was first approved as Caprelsa on 2011-04-06. It is used to treat thyroid neoplasms in the USA. It has been approved in Europe to treat thyroid neoplasms. The pharmaceutical is active against vascular endothelial growth factor receptor 2 and proto-oncogene tyrosine-protein kinase receptor Ret. In addition, it is known to target epidermal growth factor receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
endocrine system diseasesD004700
Trade Name
FDA
EMA
Caprelsa
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vandetanib
Tradename
Company
Number
Date
Products
CAPRELSASanofiN-022405 RX2011-04-06
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
caprelsaNew Drug Application2023-01-09
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
thyroid neoplasmsEFO_0003841D013964—
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Vandetanib, Caprelsa, Genzyme Corp
80674272028-08-08DP
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01E: Protein kinase inhibitors, antineoplastic and immunomodulating agents
— L01EX: Other protein kinase inhibitors in atc
— L01EX04: Vandetanib
HCPCS
No data
Clinical
Clinical Trials
108 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Thyroid neoplasmsD013964EFO_0003841—421—7
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD002289694——19
Lung neoplasmsD008175C34.90362——11
Papillary thyroid cancerD000077273443—19
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8074——112
Breast neoplasmsD001943EFO_0003869C5027———9
Colorectal neoplasmsD01517941———5
Prostatic neoplasmsD011471C6114———5
GlioblastomaD005909EFO_000051542———5
GliosarcomaD01831632———4
Pancreatic neoplasmsD010190EFO_0003860C2521———3
Head and neck neoplasmsD00625821———3
Ovarian neoplasmsD010051EFO_0003893C5613———3
Biliary tract neoplasmsD001661C24.911———2
Show 26 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AdenocarcinomaD0002303————3
Healthy volunteers/patients—3————3
Esophageal neoplasmsD004938C152————2
GliomaD005910EFO_00005202————2
LymphomaD008223C85.91————1
Lymphoproliferative disordersD008232Orphanet_2442D47.91————1
Rectal neoplasmsD0120041————1
Diffuse intrinsic pontine gliomaD0000804431————1
NeuroblastomaD009447EFO_00006211————1
PheochromocytomaD0106731————1
Show 2 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Gastrointestinal neoplasmsD005770C26.9————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVANDETANIB
INNvandetanib
Description
Vandetanib is a quinazoline that is 7-[(1-methylpiperidin-4-yl)methoxy]quinazoline bearing additional methoxy and 4-bromo-2-fluorophenylamino substituents at positions 6 and 4 respectively. Used for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. It has a role as a tyrosine kinase inhibitor and an antineoplastic agent. It is an aromatic ether, a secondary amine, a member of quinazolines, a member of piperidines, an organobromine compound and an organofluorine compound.
Classification
Small molecule
Drug classangiogenesis inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
Identifiers
PDB2IVU
CAS-ID443913-73-3
RxCUI1098413
ChEMBL IDCHEMBL24828
ChEBI ID49960
PubChem CID3081361
DrugBankDB08764
UNII IDYO460OQ37K (ChemIDplus, GSRS)
Target
Agency Approved
KDR
KDR
RET
RET
Organism
Homo sapiens
Gene name
KDR
Gene synonyms
FLK1, VEGFR2
NCBI Gene ID
3791
Protein name
vascular endothelial growth factor receptor 2
Protein synonyms
CD309, Fetal liver kinase 1, fetal liver kinase-1, FLK-1, KDR, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, tyrosine kinase growth factor receptor
Uniprot ID
Q14178
Mouse ortholog
Kdr (16542)
vascular endothelial growth factor receptor 2 (Q8VCD0)
Alternate
EGFR
EGFR
Organism
Homo sapiens
Gene name
EGFR
Gene synonyms
ERBB, ERBB1, HER1
NCBI Gene ID
1956
Protein name
epidermal growth factor receptor
Protein synonyms
avian erythroblastic leukemia viral (v-erb-b) oncogene homolog, cell growth inhibiting protein 40, cell proliferation-inducing protein 61, EGFR vIII, epidermal growth factor receptor tyrosine kinase domain, erb-b2 receptor tyrosine kinase 1, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1
Uniprot ID
Q9UMG5
Mouse ortholog
Egfr (13649)
epidermal growth factor receptor (Q01279)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 4,749 documents
View more details
Safety
Black-box Warning
Black-box warning for: Caprelsa
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
122,110 adverse events reported
View more details